

REZOLV3R

Intraperitoneal Bevacizumab for
Recurrent Malignant Ascites in
Chemotherapy-resistant Solid
Tumours: A Randomised Trial

Current Protocol Version 1.2 dated 20 Feb 2024
Approved by Concord HREC (NSW)

ANZCTR: ACTRN12624000288527

Lead by **A/Prof Katrin Sjoquist** and **Prof Micheal
Friedlander**



Study Progress - Snapshot

- REZOLV3R was approved by the Sydney Local Health District Human Research Ethics Committee at Concord Repatriation General Hospital CH62/6/2023-176 on 28 Feb 2024
- 100 participants across 3 years in 10 Australian **metropolitan and regional sites** is planned. Currently, 1 site is activated, 4 sites are in start-up, and others been contacted for feasibility.
- Services Australia data linkage approval received
- REZOLV3R was promoted in the Cancer Symptoms Trial (CST) November edition Newsletter
- Trial Steering Committee, Executive Committee and Data Safety Monitoring Boards are being setup

Site Status - Snapshot

Site	Status	Activation Date
Concord Repatriation General Hospital, NSW	Activated	20 th Sept 2024
Mater Hospital, North Sydney, NSW	Start Up <ul style="list-style-type: none">• Ethics approved	Expected Oct 2024
Northeast Health Wangaratta, VIC (Regional)	Start Up <ul style="list-style-type: none">• Ethics approved	Expected Nov 2024
Epworth Health, Freemasons, VIC	Start Up <ul style="list-style-type: none">• Ethics approved	Expected Dec 2024
Flinders' Medical Centre, SA	Start Up <ul style="list-style-type: none">• Ethics approved	Expected Q1 2025
St George Hospital, Sydney, NSW	Feasibility	Expected Q1 2025
St Vincent's, Melbourne, VIC	Feasibility	Expected Q2 2025